Rate My Professor Mohamed Donia

The Donia lab operates at the intersection of microbiology, molecular biology, biochemistry, small molecule chemistry, biosynthesis, metagenomics, and computational biology to study small-molecule-mediated interactions in diverse microbial communities such as the human gut microbiome and marine symbioses. Key research contributions include developing high-throughput approaches to define biochemical transformations by the human gut microbiome on drugs and dietary compounds, identifying microbiome-encoded resistance to the antidiabetic drug acarbose, and creating metagenomic tools like MetaBGC for discovering biosynthetic gene clusters. Notable publications encompass “Personalized Mapping of Drug Metabolism by the Human Gut Microbiome” (Cell, 2020), “The human microbiome encodes resistance to the antidiabetic drug acarbose” (Nature, 2021), “A metagenomic strategy for harnessing the chemical repertoire of the human microbiome” (Science, 2019), “A microbial factory for defensive kahalalides in a tripartite marine symbiosis” (Science, 2019), and “Localized production of defence chemicals by intracellular symbionts of Haliclona sponges” (Nature Microbiology, 2019). Donia has earned prestigious awards including the NIH Director’s New Innovator Award (2015), Kenneth Rainin Foundation Innovator and Breakthrough Awards (2015–2017), Pew Biomedical Scholar (2017), Pershing Square Sohn Prize for Young Investigators in Cancer Research (2020), and Vilcek Prize for Creative Promise in Biomedical Science (2020). His findings illuminate microbiome roles in health, disease, and therapeutic responses, advancing microbiome-targeted diagnostics and therapies.